

NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

according to § 12 in BioInvent International AB’s Articles of Association.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder’s shares in **BioInvent International AB (publ)**, Reg. No. 556537-7263 at the Annual General Meeting on 3 May 2024. The voting right is exercised in accordance with the below marked voting options.

BioInvent International AB (publ) at hand no later than 26 April 2024, kindly before 4.00 pm. CEST.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorized to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder’s decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

For further instructions, see the next page

Instructions to vote in advance by post:

- Complete the information above.
- Select the preferred voting options below.
- Print, sign and send the form in original to BioInvent International AB, Ideongatan 1, SE-223 70 Lund, Sweden, att: Stefan Ericsson. A completed and signed form may also be submitted electronically and shall be sent to stefan.ericsson@bioinvent.com.
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- If the shareholder is a legal entity, a copy of a registration certificate or a corresponding document for the legal entity shall be enclosed together with the form. A power of attorney shall be enclosed if the shareholder votes in advance by proxy.

Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this are included in the notice convening the meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The form, together with any enclosed authorization documentation, shall be received by BioInvent International AB no later than 26 April 2024. An advance vote can be withdrawn up to and including the same time by contacting the company via e-mail to stefan.ericsson@bioinvent.com, or by mail to BioInvent International AB, Ideongatan 1, SE-223 70 Lund, Sweden, att: Stefan Ericsson.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. A shareholder who has voted in advance also has the possibility to participate in the meeting room, provided that notification to attend the meeting room has been made in accordance with the instructions in the notice. If a shareholder has voted in advance, and thereafter participates at the Annual General Meeting in person or by proxy, the advance vote is still valid unless the shareholder participates in a vote during the meeting. If the shareholder during the meeting chooses to participate in a vote, the vote cast will replace the previously submitted advance vote in the relevant decision point(s).

Please note that the advance vote does not constitute a notification to attend the meeting room in person or through an authorized representative. Instructions for shareholders who wish to attend the meeting room in person or through an authorized representative is included in the notice convening the Annual General Meeting.

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the meeting and the company's website.

For information on how your personal data is processed, see the integrity policy that is available at www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Advance vote

Annual General Meeting in BioInvent International AB (publ) on 3 May 2024

The options below comprise, if not otherwise stated in the form, the proposals submitted by the board of directors and the nomination committee, which are included in the notice convening the Annual General Meeting.

<p>2. Election of Chairman of the meeting</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>3. Preparation and approval of the voting list</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>5. Determination of compliance with the rules of convocation</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>6. Approval of the agenda</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>9a. Resolutions regarding adoption of the Statement of Income and the Balance Sheet and the Consolidated Statement of Income and the Consolidated Balance Sheet</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>9b. Resolutions regarding appropriation of the company's result according to the adopted Balance Sheet</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>9c. Resolutions regarding discharge from liability of the Board of Directors and the Managing Director</p>
<p>9c.1 Leonard Kruimer (<i>Chairman of the Board</i>)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>9c.2 Natalie Berner (<i>Board member</i>)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>

9c.3 Kristoffer Bissessar (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.4 Erik Esveld (<i>Board member, from and including 27 April 2023</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.5 Thomas Hecht (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.6 Nanna Lüneborg (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.7 Vincent Ossipow (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.8 Bernd Seizinger (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.9 Elin Birgersson (<i>Board member, employee representative</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.10 Martin Pålsson (<i>Board member, employee representative</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.11 Vessela Alexieva (<i>deputy Board member, employee representative and former Board member, employee representative, regarding the period from and including 1 January 2023 up to and including 17 February 2023</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.12 Dharminder Chahal (<i>former Board member, regarding the period from and including 1 January 2023 up to and including 27 April 2023</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
9c.13 Martin Welschhof (<i>Chief Executive Officer</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>

10. Resolution on approval of remuneration report Yes <input type="checkbox"/> No <input type="checkbox"/>
11. Establishment of the number of members of the Board of Directors
11.1 Number of members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
11.2 Number of deputy members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
12. Establishment of fees for members of the Board of Directors and the Auditor
12.1 Fees for the members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
12.2 Fees for the Auditor Yes <input type="checkbox"/> No <input type="checkbox"/>
13. Election of members of the Board of Directors
13.1 Natalie Berner (<i>re-election</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
13.2 Kristoffer Bissessar (<i>re-election</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
13.3 Thomas Hecht (<i>re-election</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
13.4 Leonard Kruimer (<i>re-election</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
13.5 Nanna Lüneborg (<i>re-election</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
13.6 Vincent Ossipow (<i>re-election</i>)

Yes <input type="checkbox"/> No <input type="checkbox"/>
13.7 Bernd Seizinger (<i>re-election</i>)
Yes <input type="checkbox"/> No <input type="checkbox"/>
13.8 Laura Lassouw-Polman (<i>new election</i>)
Yes <input type="checkbox"/> No <input type="checkbox"/>
14. Election of Chairman of the Board of Directors
Yes <input type="checkbox"/> No <input type="checkbox"/>
15. Election of Auditor
Yes <input type="checkbox"/> No <input type="checkbox"/>
16. Resolution on guidelines for remuneration to senior executives
Yes <input type="checkbox"/> No <input type="checkbox"/>
17. Resolution on (a) implementation of Option Program 2024/2026 and (b) directed issue of warrants and approval of transfer of warrants to fulfil the company's commitments under the option program and to secure social security charges
Yes <input type="checkbox"/> No <input type="checkbox"/>
18. Resolution on authorization of the Board of Directors to resolve on new shares issue
Yes <input type="checkbox"/> No <input type="checkbox"/>